COVID-19 survivors with calcineurin-inhibitors-treated rheumatoid arthritis

Mod Rheumatol Case Rep. 2022 Jan 7;6(1):10-13. doi: 10.1093/mrcr/rxab023.

Abstract

We report two cases recovered from coronavirus disease 2019 with rheumatoid arthritis which had been in remission or low disease activity by taking calcineurin inhibitor (CNI). Both cases had moderate to severe pneumonia treated with intravenous dexamethasone or in the severe case remdesivir in addition to it. These cases suggest that the use of CNI may have affected the improvement of severe pneumonia.

Keywords: Coronavirus disease 2019; calcineurin inhibitor; pneumonia; rheumatoid arthritis; risk factors.

Publication types

  • Case Reports

MeSH terms

  • Adenosine Monophosphate / analogs & derivatives
  • Adenosine Monophosphate / therapeutic use
  • Alanine / analogs & derivatives
  • Alanine / therapeutic use
  • Arthritis, Rheumatoid* / drug therapy
  • COVID-19 Drug Treatment*
  • Calcineurin
  • Calcineurin Inhibitors* / therapeutic use
  • Dexamethasone / therapeutic use
  • Humans
  • Survivors

Substances

  • Calcineurin Inhibitors
  • remdesivir
  • Adenosine Monophosphate
  • Dexamethasone
  • Calcineurin
  • Alanine